{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:10:21Z","timestamp":1789236621021,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Background\n<\/jats:title>\n                <jats:p>Optimum glycemic control is necessary to reduce and even prevent the risk of micro- and macrovascular complications of type 1 diabetes mellitus (T1DM). The main aim of this study was to assess the prevalence of T1DM patients with adequate glycemic control in 4 Arabian Gulf countries.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study was a multicenter, observational, cross-sectional disease registry. Data were collected from adult T1DM patients who were treated with insulin within 6\u2009months prior to the study visit.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Out of 241 patients whose data were eligible for primary endpoint analysis, 27.4% had adequate glycemic control (HbA1c\u2009&lt;\u20097%). The patients\u2019 age ranged from 18 to 64\u2009years, and 53% were males. The mean (SD) duration of diabetes was 14.6 (9) years and the mean HbA1c was 8.11 (1.8) %. At the time of T1DM diagnosis, mean HbA1c was 10.7 (2.17) %. About 98% of the patients were normotensive and the lipid profile of patients was found to be optimal. The main variables associated with adequate glycemic control were low HbA1c at diagnosis (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and absence of a family history of diabetes (<jats:italic>P<\/jats:italic>\u2009=\u20090.002).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We found that the glycemic control of T1DM adult patients in Kuwait, UAE, Oman and Bahrain is suboptimal. More efforts are necessary to pinpoint the causes of inadequate control in this population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-022-00946-3","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T13:03:13Z","timestamp":1643634193000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Glycemic control of adult patients with type 1 diabetes mellitus in Arabian Gulf Countries; PREDICT"],"prefix":"10.1186","volume":"22","author":[{"given":"Khadija","family":"Hafidh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabila Ahmed","family":"Abdella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"key":"946_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1651-2227.1999.tb14333.x","volume":"88","author":"A Green","year":"1999","unstructured":"Green A. Epidemiology of type 1 (insulin-dependent) diabetes mellitus: public health implications in the Middle East. Acta Paediatr. 1999;88:8\u201310. https:\/\/doi.org\/10.1111\/j.1651-2227.1999.tb14333.x.","journal-title":"Acta Paediatr"},{"key":"946_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.dsx.2012.08.006","volume":"6","author":"SK Kota","year":"2012","unstructured":"Kota SK, Meher LK, Jammula S, Kota SK, Modi KD. Clinical profile of coexisting conditions in type 1 diabetes mellitus patients, Diabetes Metab. Syndr. Clin. Res Rev. 2012;6:70\u20136. https:\/\/doi.org\/10.1016\/j.dsx.2012.08.006.","journal-title":"Res Rev"},{"key":"946_CR3","unstructured":"Diabetes Federation International, IDF Diabetes Atlas 2019; 2019. http:\/\/www.idf.org\/about-diabetes\/facts-figures."},{"key":"946_CR4","unstructured":"IDF Diabetes Atlas, 2017. https:\/\/www.idf.org\/e-library\/epidemiology-research\/diabetes-atlas\/134-idf-diabetes-atlas-8th-edition.html."},{"key":"946_CR5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.2337\/diaclin.29.3.116","volume":"29","author":"MJ Fowler","year":"2011","unstructured":"Fowler MJ. Microvascular and macrovascular complications of Diabetes. Clin Diabetes. 2011;29:116\u201322. https:\/\/doi.org\/10.2337\/diaclin.29.3.116.","journal-title":"Clin Diabetes"},{"key":"946_CR6","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1056\/NEJMoa1408214","volume":"371","author":"M Lind","year":"2014","unstructured":"Lind M, Svensson A-M, Kosiborod M, Gudbj\u00f6rnsdottir S, Pivodic A, Wedel H, et al. Glycemic control and excess mortality in type 1 Diabetes. N Engl J Med. 2014;371:1972\u201382. https:\/\/doi.org\/10.1056\/NEJMoa1408214.","journal-title":"N Engl J Med"},{"key":"946_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.5001\/omj.2013.46","volume":"28","author":"S Ashraff","year":"2013","unstructured":"Ashraff S, Siddiqui MA, Carline TE. The psychosocial impact of Diabetes in adolescents: a review, Oman. Med J. 2013;28:159\u201362. https:\/\/doi.org\/10.5001\/omj.2013.46.","journal-title":"Med J"},{"key":"946_CR8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.7326\/M17-1259","volume":"167","author":"JJ Chamberlain","year":"2017","unstructured":"Chamberlain JJ, Kalyani RR, Leal S, Rhinehart AS, Shubrook JH, Skolnik N, et al. Treatment of type 1 Diabetes: synopsis of the 2017 American Diabetes Association standards of medical Care in Diabetes. Ann Intern Med. 2017;167:493. https:\/\/doi.org\/10.7326\/M17-1259.","journal-title":"Ann Intern Med"},{"key":"946_CR9","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s12325-016-0370-1","volume":"33","author":"JB McGill","year":"2016","unstructured":"McGill JB, Ahn D, Edelman SV, Kilpatrick CR, Santos Cavaiola T. Making insulin accessible: does inhaled insulin fill an unmet need? Adv Ther. 2016;33:1267\u201378. https:\/\/doi.org\/10.1007\/s12325-016-0370-1.","journal-title":"Adv Ther"},{"key":"946_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1758-5996-2-14","volume":"2","author":"S Kalra","year":"2010","unstructured":"Kalra S, Kalra B, Sharma A. Prevalence of type 1 diabetes mellitus in Karnal district, Haryana state, India. Diabetol Metab Syndr. 2010;2:14. https:\/\/doi.org\/10.1186\/1758-5996-2-14.","journal-title":"Diabetol Metab Syndr"},{"key":"946_CR11","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.2337\/dc12-2480","volume":"36","author":"ER Seaquist","year":"2013","unstructured":"Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and Diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36:1384\u201395. https:\/\/doi.org\/10.2337\/dc12-2480.","journal-title":"Diabetes Care"},{"key":"946_CR12","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"DM Nathan","year":"1993","unstructured":"Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, et al. The effect of intensive treatment of Diabetes on the development and progression of Long-term complications in insulin-dependent Diabetes mellitus. N Engl J Med. 1993;329:977\u201386. https:\/\/doi.org\/10.1056\/NEJM199309303291401.","journal-title":"N Engl J Med"},{"key":"946_CR13","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1056\/NEJMoa052187","volume":"353","author":"The Diabetes Control and Complications Trial\/Epidemiology of Diabetes, and C. (DCCT\/EDIC) S.R.G","year":"2005","unstructured":"The Diabetes Control and Complications Trial\/Epidemiology of Diabetes, and C. (DCCT\/EDIC) S.R.G. Group, intensive Diabetes treatment and cardiovascular disease in patients with type 1 Diabetes. N Engl J Med. 2005;353:2643\u201353. https:\/\/doi.org\/10.1056\/NEJMoa052187.","journal-title":"N Engl J Med"},{"key":"946_CR14","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.2337\/dci18-0023","volume":"41","author":"JL Chiang","year":"2018","unstructured":"Chiang JL, Maahs DM, Garvey KC, Hood KK, Laffel LM, Weinzimer SA, et al. Type 1 Diabetes in children and adolescents: a position statement by the American Diabetes Association. Diabetes Care. 2018;41:2026\u201344. https:\/\/doi.org\/10.2337\/dci18-0023.","journal-title":"Diabetes Care"},{"key":"946_CR15","unstructured":"National Clinical Guideline Centre, type 1 diabetes in adults: diagnosis and management. 2015. https:\/\/www.nice.org.uk\/guidance\/ng17\/evidence\/full-guideline-pdf-435400241."},{"key":"946_CR16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.17925\/EE.2019.15.2.70","volume":"15","author":"C Zimmerman","year":"2019","unstructured":"Zimmerman C, Albanese-O\u2019Neill A, Haller MJ. Advances in type 1 Diabetes technology over the last decade. Eur Endocrinol. 2019;15:70 https:\/\/doi.org\/10.17925\/EE.2019.15.2.70.","journal-title":"Eur Endocrinol"},{"key":"946_CR17","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/dme.12676","volume":"32","author":"JA McKnight","year":"2015","unstructured":"McKnight JA, Wild SH, Lamb MJE, Cooper MN, Jones TW, Davis EA, et al. Glycaemic control of type 1 diabetes in clinical practice early in the 21st century: an international comparison. Diabet Med. 2015;32:1036\u201350. https:\/\/doi.org\/10.1111\/dme.12676.","journal-title":"Diabet Med"},{"key":"946_CR18","doi-asserted-by":"publisher","unstructured":"Renard E, Ikegami H, Daher Vianna AG, Pozzilli P, Brette S, Bosnyak Z, et al. The SAGE study: global observational analysis of glycaemic control, hypoglycaemia and diabetes management in T1DM, Diabetes. Metab Res Rev. 2021. https:\/\/doi.org\/10.1002\/dmrr.3430.","DOI":"10.1002\/dmrr.3430"},{"key":"946_CR19","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1007\/s00125-017-4364-6","volume":"60","author":"R Livingstone","year":"2017","unstructured":"Livingstone R, Boyle JG, Petrie JR. A new perspective on metformin therapy in type 1 diabetes. Diabetologia. 2017;60:1594\u2013600. https:\/\/doi.org\/10.1007\/s00125-017-4364-6.","journal-title":"Diabetologia."},{"key":"946_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2983","volume":"34","author":"H Meng","year":"2018","unstructured":"Meng H, Zhang A, Liang Y, Hao J, Zhang X, Lu J. Effect of metformin on glycaemic control in patients with type 1 diabetes: a meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2018;34:e2983. https:\/\/doi.org\/10.1002\/dmrr.2983.","journal-title":"Diabetes Metab Res Rev"},{"key":"946_CR21","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/S2213-8587(17)30308-X","volume":"5","author":"P Dandona","year":"2017","unstructured":"Dandona P, Mathieu C, Phillip M, Hansen L, Griffen SC, Tsch\u00f6pe D, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5:864\u201376 https:\/\/doi.org\/10.1016\/S2213-8587(17)30308-X.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"946_CR22","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.2337\/dc18-1749","volume":"41","author":"J Rosenstock","year":"2018","unstructured":"Rosenstock J, Marquard J, Laffel LM, Neubacher D, Kaspers S, Cherney DZ, et al. Empagliflozin as adjunctive to insulin therapy in type 1 Diabetes: the EASE trials. Diabetes Care. 2018;41:2560\u20139. https:\/\/doi.org\/10.2337\/dc18-1749.","journal-title":"Diabetes Care"},{"key":"946_CR23","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s13300-017-0282-3","volume":"8","author":"W Wang","year":"2017","unstructured":"Wang W, Liu H, Xiao S, Liu S, Li X, Yu P. Effects of insulin plus glucagon-like Peptide-1 receptor agonists (GLP-1RAs) in treating type 1 Diabetes mellitus: a systematic review and Meta-analysis. Diabetes Ther. 2017;8:727\u201338. https:\/\/doi.org\/10.1007\/s13300-017-0282-3.","journal-title":"Diabetes Ther"},{"key":"946_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131837","volume":"10","author":"E Maddaloni","year":"2015","unstructured":"Maddaloni E, Lessan N, Al Tikriti A, Buzzetti R, Pozzilli P, Barakat MT. Latent autoimmune Diabetes in adults in the United Arab Emirates: clinical features and factors related to insulin-requirement. PLoS One. 2015;10:e0131837. https:\/\/doi.org\/10.1371\/journal.pone.0131837.","journal-title":"PLoS One"},{"key":"946_CR25","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2337\/ds15-0047","volume":"29","author":"KS O\u2019Neal","year":"2016","unstructured":"O\u2019Neal KS, Johnson JL, Panak RL. Recognizing and appropriately treating latent autoimmune Diabetes in adults. Diabetes Spectr. 2016;29:249\u201352. https:\/\/doi.org\/10.2337\/ds15-0047.","journal-title":"Diabetes Spectr"},{"key":"946_CR26","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.2337\/dbi20-0017","volume":"69","author":"R Buzzetti","year":"2020","unstructured":"Buzzetti R, Tuomi T, Mauricio D, Pietropaolo M, Zhou Z, Pozzilli P, et al. Management of Latent Autoimmune Diabetes in adults: a consensus statement from an international expert panel. Diabetes. 2020;69:2037\u201347. https:\/\/doi.org\/10.2337\/dbi20-0017.","journal-title":"Diabetes."},{"key":"946_CR27","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.diabres.2006.01.013","volume":"73","author":"M Kobayashi","year":"2006","unstructured":"Kobayashi M, Yamazaki K, Hirao K, Oishi M, Kanatsuka A, Yamauchi M, et al. The status of diabetes control and antidiabetic drug therapy in Japan\u2014a cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM 1). Diabetes Res Clin Pract. 2006;73:198\u2013204. https:\/\/doi.org\/10.1016\/j.diabres.2006.01.013.","journal-title":"Diabetes Res Clin Pract"},{"key":"946_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/5308582","volume":"2018","author":"Q Wang","year":"2018","unstructured":"Wang Q, Long M, Qu H, Shen R, Zhang R, Xu J, et al. DPP-4 inhibitors as treatments for type 1 Diabetes mellitus: a systematic review and Meta-analysis. J Diabetes Res. 2018;2018:1\u201310. https:\/\/doi.org\/10.1155\/2018\/5308582.","journal-title":"J Diabetes Res"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-00946-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-022-00946-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-00946-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T13:09:34Z","timestamp":1643634574000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-022-00946-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["946"],"URL":"https:\/\/doi.org\/10.1186\/s12902-022-00946-3","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,31]]},"assertion":[{"value":"6 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles laid down by the 18th World Medical Assembly (Helsinki, 1964) including all subsequent amendments. This study was also conducted in compliance with all international guidelines, and national laws and regulations of the countries in which the registry was performed, as well as any applicable guidelines. Each participating country locally ensured that all necessary regulatory submissions (e.g. Institutional Review Board\/ Ethics Committee) were performed in accordance with local guidelines including local data protection regulations. All patients provided their written informed consent before the initiation of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}